Global Hematological Malignancies
Global Hematological Malignancies

Hematological Malignancies Comprehensive Study by Type (Leukemia, Lymphoma, Myeloma), Route of Administration (Oral, Parenteral, Others), Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), Therapy Type (Hemotherapy, Immunotherapy, Targeted Therapy), End- User (Hospitals, Homecare, Specialty Centres, Others) Players and Region - Global Market Outlook to 2026

Hematological Malignancies Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 244 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Hematological Malignancies Market Scope?
Hematologic malignancies are a serious and life-threatening cancer that affects either production and performance of blood cells like bone marrow and tissues which ends up in dysfunctional of the lymphatic system. The characteristics sign and symptoms of hematologic malignancies is severe abdominal pain, bone and joints pain, bit by bit weight loss, dark spots, excessive or easy bruising and weakness. Medicine cancer usually referred to as hematological malignancy, maybe a class of cancer that affects the body fluid nodes, blood, and bone marrow. It includes various forms like malignant neoplastic disease, leukemia, and myeloma. Leukemia is a malignancy during which abnormal white blood cells are shaped within the bone marrow. The malignant neoplastic disease may be a blood cancer that develops within the systema lymphaticum. Malignant neoplasm is cancer-related to the plasma of white blood cells. Associated with cancer is caused because of long exposure to toxic substances like chemical agents and radiation, genetic predisposition, viral infections, complicated patient profiles, improper assessment, and risks hematologic different diseases with decreased immunity.

The Hematological Malignancies market study is being classified by Type (Leukemia, Lymphoma and Myeloma) and major geographies with country level break-up.

The hematological Malignancies market is increasing due to the increasing number of cases of diseases. Investments by leading pharmaceutical players to develop new drugs are expected to boost the growth of the hematological cancers market. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Hematological Malignancies market throughout the predicted period.

Novartis International AG (Switzerland), Celgene Corporation (United States), AbbVie, Inc. (United States), Bristol-Myers Squibb Company (United States), GlaxoSmithKline plc (United Kingdom), Otsuka Pharmaceutical Co., Ltd., (Japan) and Teva Pharmaceutical Industries Ltd. (Israel) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Hematological Malignancies market by Type, Application and Region.

On the basis of geography, the market of Hematological Malignancies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In March 2021, Sanofi S.A. received US FDA approval for its Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. and In February 2021, TG Therapeutics, Inc received US FDA accelerated approval for its UKONIQ (umbralisib), an oral, once-daily, inhibitor of phosphoinositide 3 kinases (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL).


Influencing Market Trend
  • Rising Trend of Patent Protection

Market Drivers
  • High Prevalence of Hematologic Malignancies
  • High Diagnostics Rate and Vulnerable Geriatric Population
  • Skilled Professionals in The Healthcare Sector
  • Growing Incidence of Blood Cancer

Opportunities
  • Launches of Drugs Annually
  • Advances in Pharmaceuticals and Biotechnological Sectors or Industries

Restraints
  • High Treatment Cost Significantly
  • Patent Expiration

Challenges
  • Less Awareness About Cancer Treatments
  • Unfavorable Reimbursement Policies


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Hematological Malignancies Treatment, Venture Capitalists and Private Equity Firms and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Frequently Asked Questions (FAQ):

1. At what growth rate would the Hematological Malignancies market expands?
The Global Hematological Malignancies market is expected to see a growth of % during projected year 2020 to 2026.

2. Who are the prominent players of the Global Hematological Malignancies market?
The prominent players of Global Hematological Malignancies market are Novartis International AG (Switzerland), Celgene Corporation (United States), AbbVie, Inc. (United States), Bristol-Myers Squibb Company (United States), GlaxoSmithKline plc (United Kingdom), Otsuka Pharmaceutical Co., Ltd., (Japan) and Teva Pharmaceutical Industries Ltd. (Israel), to name a few.

3. What are the top priorities to focus for Hematological Malignancies marketís growth?
In this highly competitive & fast evolving Hematological Malignancies industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Report Objectives / Segmentation Covered
By Type
  • Leukemia
  • Lymphoma
  • Myeloma
By Route of Administration
  • Oral
  • Parenteral
  • Others

By Distribution Channel
  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies

By Therapy Type
  • Hemotherapy
  • Immunotherapy
  • Targeted Therapy

By End- User
  • Hospitals
  • Homecare
  • Specialty Centres
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Hematologic Malignancies
      • 3.2.2. High Diagnostics Rate and Vulnerable Geriatric Population
      • 3.2.3. Skilled Professionals in The Healthcare Sector
      • 3.2.4. Growing Incidence of Blood Cancer
    • 3.3. Market Challenges
      • 3.3.1. Less Awareness About Cancer Treatments
      • 3.3.2. Unfavorable Reimbursement Policies
    • 3.4. Market Trends
      • 3.4.1. Rising Trend of Patent Protection
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hematological Malignancies, by Type, Route of Administration, Distribution Channel, Therapy Type, End- User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hematological Malignancies (Value)
      • 5.2.1. Global Hematological Malignancies by: Type (Value)
        • 5.2.1.1. Leukemia
        • 5.2.1.2. Lymphoma
        • 5.2.1.3. Myeloma
      • 5.2.2. Global Hematological Malignancies by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
        • 5.2.2.3. Others
      • 5.2.3. Global Hematological Malignancies by: Distribution Channel (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Hematological Malignancies by: Therapy Type (Value)
        • 5.2.4.1. Hemotherapy
        • 5.2.4.2. Immunotherapy
        • 5.2.4.3. Targeted Therapy
      • 5.2.5. Global Hematological Malignancies by: End- User (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Homecare
        • 5.2.5.3. Specialty Centres
        • 5.2.5.4. Others
      • 5.2.6. Global Hematological Malignancies Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Hematological Malignancies (Price)
      • 5.3.1. Global Hematological Malignancies by: Type (Price)
  • 6. Hematological Malignancies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Celgene Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol-Myers Squibb Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Otsuka Pharmaceutical Co., Ltd., (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Hematological Malignancies Sale, by Type, Route of Administration, Distribution Channel, Therapy Type, End- User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hematological Malignancies (Value)
      • 7.2.1. Global Hematological Malignancies by: Type (Value)
        • 7.2.1.1. Leukemia
        • 7.2.1.2. Lymphoma
        • 7.2.1.3. Myeloma
      • 7.2.2. Global Hematological Malignancies by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
        • 7.2.2.3. Others
      • 7.2.3. Global Hematological Malignancies by: Distribution Channel (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Hematological Malignancies by: Therapy Type (Value)
        • 7.2.4.1. Hemotherapy
        • 7.2.4.2. Immunotherapy
        • 7.2.4.3. Targeted Therapy
      • 7.2.5. Global Hematological Malignancies by: End- User (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Homecare
        • 7.2.5.3. Specialty Centres
        • 7.2.5.4. Others
      • 7.2.6. Global Hematological Malignancies Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Hematological Malignancies (Price)
      • 7.3.1. Global Hematological Malignancies by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hematological Malignancies: by Type(USD Million)
  • Table 2. Hematological Malignancies Leukemia , by Region USD Million (2015-2020)
  • Table 3. Hematological Malignancies Lymphoma , by Region USD Million (2015-2020)
  • Table 4. Hematological Malignancies Myeloma , by Region USD Million (2015-2020)
  • Table 5. Hematological Malignancies: by Route of Administration(USD Million)
  • Table 6. Hematological Malignancies Oral , by Region USD Million (2015-2020)
  • Table 7. Hematological Malignancies Parenteral , by Region USD Million (2015-2020)
  • Table 8. Hematological Malignancies Others , by Region USD Million (2015-2020)
  • Table 9. Hematological Malignancies: by Distribution Channel(USD Million)
  • Table 10. Hematological Malignancies Hospitals , by Region USD Million (2015-2020)
  • Table 11. Hematological Malignancies Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 12. Hematological Malignancies Online Pharmacies , by Region USD Million (2015-2020)
  • Table 13. Hematological Malignancies: by Therapy Type(USD Million)
  • Table 14. Hematological Malignancies Hemotherapy , by Region USD Million (2015-2020)
  • Table 15. Hematological Malignancies Immunotherapy , by Region USD Million (2015-2020)
  • Table 16. Hematological Malignancies Targeted Therapy , by Region USD Million (2015-2020)
  • Table 17. Hematological Malignancies: by End- User(USD Million)
  • Table 18. Hematological Malignancies Hospitals , by Region USD Million (2015-2020)
  • Table 19. Hematological Malignancies Homecare , by Region USD Million (2015-2020)
  • Table 20. Hematological Malignancies Specialty Centres , by Region USD Million (2015-2020)
  • Table 21. Hematological Malignancies Others , by Region USD Million (2015-2020)
  • Table 22. South America Hematological Malignancies, by Country USD Million (2015-2020)
  • Table 23. South America Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 24. South America Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 25. South America Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 26. South America Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 27. South America Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 28. Brazil Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 29. Brazil Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 30. Brazil Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 31. Brazil Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 32. Brazil Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 33. Argentina Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 34. Argentina Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 35. Argentina Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 36. Argentina Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 37. Argentina Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 38. Rest of South America Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 39. Rest of South America Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 40. Rest of South America Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 41. Rest of South America Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 42. Rest of South America Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 43. Asia Pacific Hematological Malignancies, by Country USD Million (2015-2020)
  • Table 44. Asia Pacific Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 45. Asia Pacific Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 46. Asia Pacific Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 47. Asia Pacific Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 48. Asia Pacific Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 49. China Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 50. China Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 51. China Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 52. China Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 53. China Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 54. Japan Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 55. Japan Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 56. Japan Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 57. Japan Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 58. Japan Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 59. India Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 60. India Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 61. India Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 62. India Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 63. India Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 64. South Korea Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 65. South Korea Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 66. South Korea Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 67. South Korea Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 68. South Korea Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 69. Taiwan Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 70. Taiwan Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 71. Taiwan Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 72. Taiwan Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 73. Taiwan Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 74. Australia Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 75. Australia Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 76. Australia Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 77. Australia Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 78. Australia Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 84. Europe Hematological Malignancies, by Country USD Million (2015-2020)
  • Table 85. Europe Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 86. Europe Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 87. Europe Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 88. Europe Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 89. Europe Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 90. Germany Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 91. Germany Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 92. Germany Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 93. Germany Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 94. Germany Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 95. France Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 96. France Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 97. France Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 98. France Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 99. France Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 100. Italy Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 101. Italy Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 102. Italy Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 103. Italy Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 104. Italy Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 105. United Kingdom Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 106. United Kingdom Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 107. United Kingdom Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 108. United Kingdom Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 109. United Kingdom Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 110. Netherlands Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 111. Netherlands Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 112. Netherlands Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 113. Netherlands Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 114. Netherlands Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 115. Rest of Europe Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 116. Rest of Europe Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 117. Rest of Europe Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 118. Rest of Europe Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 119. Rest of Europe Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 120. MEA Hematological Malignancies, by Country USD Million (2015-2020)
  • Table 121. MEA Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 122. MEA Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 123. MEA Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 124. MEA Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 125. MEA Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 126. Middle East Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 127. Middle East Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 128. Middle East Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 129. Middle East Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 130. Middle East Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 131. Africa Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 132. Africa Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 133. Africa Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 134. Africa Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 135. Africa Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 136. North America Hematological Malignancies, by Country USD Million (2015-2020)
  • Table 137. North America Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 138. North America Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 139. North America Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 140. North America Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 141. North America Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 142. United States Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 143. United States Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 144. United States Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 145. United States Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 146. United States Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 147. Canada Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 148. Canada Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 149. Canada Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 150. Canada Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 151. Canada Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 152. Mexico Hematological Malignancies, by Type USD Million (2015-2020)
  • Table 153. Mexico Hematological Malignancies, by Route of Administration USD Million (2015-2020)
  • Table 154. Mexico Hematological Malignancies, by Distribution Channel USD Million (2015-2020)
  • Table 155. Mexico Hematological Malignancies, by Therapy Type USD Million (2015-2020)
  • Table 156. Mexico Hematological Malignancies, by End- User USD Million (2015-2020)
  • Table 157. Hematological Malignancies: by Type(USD/Units)
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Hematological Malignancies: by Type(USD Million)
  • Table 166. Hematological Malignancies Leukemia , by Region USD Million (2021-2026)
  • Table 167. Hematological Malignancies Lymphoma , by Region USD Million (2021-2026)
  • Table 168. Hematological Malignancies Myeloma , by Region USD Million (2021-2026)
  • Table 169. Hematological Malignancies: by Route of Administration(USD Million)
  • Table 170. Hematological Malignancies Oral , by Region USD Million (2021-2026)
  • Table 171. Hematological Malignancies Parenteral , by Region USD Million (2021-2026)
  • Table 172. Hematological Malignancies Others , by Region USD Million (2021-2026)
  • Table 173. Hematological Malignancies: by Distribution Channel(USD Million)
  • Table 174. Hematological Malignancies Hospitals , by Region USD Million (2021-2026)
  • Table 175. Hematological Malignancies Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 176. Hematological Malignancies Online Pharmacies , by Region USD Million (2021-2026)
  • Table 177. Hematological Malignancies: by Therapy Type(USD Million)
  • Table 178. Hematological Malignancies Hemotherapy , by Region USD Million (2021-2026)
  • Table 179. Hematological Malignancies Immunotherapy , by Region USD Million (2021-2026)
  • Table 180. Hematological Malignancies Targeted Therapy , by Region USD Million (2021-2026)
  • Table 181. Hematological Malignancies: by End- User(USD Million)
  • Table 182. Hematological Malignancies Hospitals , by Region USD Million (2021-2026)
  • Table 183. Hematological Malignancies Homecare , by Region USD Million (2021-2026)
  • Table 184. Hematological Malignancies Specialty Centres , by Region USD Million (2021-2026)
  • Table 185. Hematological Malignancies Others , by Region USD Million (2021-2026)
  • Table 186. South America Hematological Malignancies, by Country USD Million (2021-2026)
  • Table 187. South America Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 188. South America Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 189. South America Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 190. South America Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 191. South America Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 192. Brazil Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 193. Brazil Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 194. Brazil Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 195. Brazil Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 196. Brazil Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 197. Argentina Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 198. Argentina Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 199. Argentina Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 200. Argentina Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 201. Argentina Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 202. Rest of South America Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 203. Rest of South America Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 204. Rest of South America Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 205. Rest of South America Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 206. Rest of South America Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 207. Asia Pacific Hematological Malignancies, by Country USD Million (2021-2026)
  • Table 208. Asia Pacific Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 209. Asia Pacific Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 210. Asia Pacific Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 211. Asia Pacific Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 212. Asia Pacific Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 213. China Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 214. China Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 215. China Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 216. China Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 217. China Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 218. Japan Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 219. Japan Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 220. Japan Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 221. Japan Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 222. Japan Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 223. India Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 224. India Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 225. India Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 226. India Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 227. India Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 228. South Korea Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 229. South Korea Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 230. South Korea Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 231. South Korea Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 232. South Korea Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 233. Taiwan Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 234. Taiwan Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 235. Taiwan Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 236. Taiwan Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 237. Taiwan Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 238. Australia Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 239. Australia Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 240. Australia Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 241. Australia Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 242. Australia Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 243. Rest of Asia-Pacific Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 244. Rest of Asia-Pacific Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 245. Rest of Asia-Pacific Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 246. Rest of Asia-Pacific Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 247. Rest of Asia-Pacific Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 248. Europe Hematological Malignancies, by Country USD Million (2021-2026)
  • Table 249. Europe Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 250. Europe Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 251. Europe Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 252. Europe Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 253. Europe Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 254. Germany Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 255. Germany Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 256. Germany Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 257. Germany Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 258. Germany Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 259. France Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 260. France Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 261. France Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 262. France Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 263. France Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 264. Italy Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 265. Italy Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 266. Italy Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 267. Italy Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 268. Italy Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 269. United Kingdom Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 270. United Kingdom Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 271. United Kingdom Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 272. United Kingdom Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 273. United Kingdom Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 274. Netherlands Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 275. Netherlands Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 276. Netherlands Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 277. Netherlands Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 278. Netherlands Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 279. Rest of Europe Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 280. Rest of Europe Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 281. Rest of Europe Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 282. Rest of Europe Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 283. Rest of Europe Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 284. MEA Hematological Malignancies, by Country USD Million (2021-2026)
  • Table 285. MEA Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 286. MEA Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 287. MEA Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 288. MEA Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 289. MEA Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 290. Middle East Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 291. Middle East Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 292. Middle East Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 293. Middle East Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 294. Middle East Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 295. Africa Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 296. Africa Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 297. Africa Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 298. Africa Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 299. Africa Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 300. North America Hematological Malignancies, by Country USD Million (2021-2026)
  • Table 301. North America Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 302. North America Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 303. North America Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 304. North America Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 305. North America Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 306. United States Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 307. United States Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 308. United States Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 309. United States Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 310. United States Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 311. Canada Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 312. Canada Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 313. Canada Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 314. Canada Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 315. Canada Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 316. Mexico Hematological Malignancies, by Type USD Million (2021-2026)
  • Table 317. Mexico Hematological Malignancies, by Route of Administration USD Million (2021-2026)
  • Table 318. Mexico Hematological Malignancies, by Distribution Channel USD Million (2021-2026)
  • Table 319. Mexico Hematological Malignancies, by Therapy Type USD Million (2021-2026)
  • Table 320. Mexico Hematological Malignancies, by End- User USD Million (2021-2026)
  • Table 321. Hematological Malignancies: by Type(USD/Units)
  • Table 322. Research Programs/Design for This Report
  • Table 323. Key Data Information from Secondary Sources
  • Table 324. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hematological Malignancies: by Type USD Million (2015-2020)
  • Figure 5. Global Hematological Malignancies: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Hematological Malignancies: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Hematological Malignancies: by Therapy Type USD Million (2015-2020)
  • Figure 8. Global Hematological Malignancies: by End- User USD Million (2015-2020)
  • Figure 9. South America Hematological Malignancies Share (%), by Country
  • Figure 10. Asia Pacific Hematological Malignancies Share (%), by Country
  • Figure 11. Europe Hematological Malignancies Share (%), by Country
  • Figure 12. MEA Hematological Malignancies Share (%), by Country
  • Figure 13. North America Hematological Malignancies Share (%), by Country
  • Figure 14. Global Hematological Malignancies: by Type USD/Units (2015-2020)
  • Figure 15. Global Hematological Malignancies share by Players 2020 (%)
  • Figure 16. Global Hematological Malignancies share by Players (Top 3) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 21. Celgene Corporation (United States) Revenue: by Geography 2020
  • Figure 22. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. AbbVie, Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 25. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 26. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 28. Otsuka Pharmaceutical Co., Ltd., (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Otsuka Pharmaceutical Co., Ltd., (Japan) Revenue: by Geography 2020
  • Figure 30. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 32. Global Hematological Malignancies: by Type USD Million (2021-2026)
  • Figure 33. Global Hematological Malignancies: by Route of Administration USD Million (2021-2026)
  • Figure 34. Global Hematological Malignancies: by Distribution Channel USD Million (2021-2026)
  • Figure 35. Global Hematological Malignancies: by Therapy Type USD Million (2021-2026)
  • Figure 36. Global Hematological Malignancies: by End- User USD Million (2021-2026)
  • Figure 37. South America Hematological Malignancies Share (%), by Country
  • Figure 38. Asia Pacific Hematological Malignancies Share (%), by Country
  • Figure 39. Europe Hematological Malignancies Share (%), by Country
  • Figure 40. MEA Hematological Malignancies Share (%), by Country
  • Figure 41. North America Hematological Malignancies Share (%), by Country
  • Figure 42. Global Hematological Malignancies: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Novartis International AG (Switzerland)
  • Celgene Corporation (United States)
  • AbbVie, Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Otsuka Pharmaceutical Co., Ltd., (Japan)
  • Teva Pharmaceutical Industries Ltd. (Israel)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation